Zhejiang Jolly Pharmaceutical Adjusts Evaluation Amid Mixed Financial Performance Indicators

Zhejiang Jolly Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a nuanced view of the company's performance metrics and market position. In the latest quarter ending March 2026, Zhejiang Jolly reported notable figures, including an operating cash flow of CNY 572.84 million, which stands as the highest recorded. Additionally, the company experienced a reduction in raw material costs by 6.47% year-over-year, contributing positively to its financial health. The net sales for the quarter also reached a peak of CNY 897.8 million. Despite these positive indicators, the stock has faced challenges, generating a return of -23.45% over the past year. While profits have increased by 19.1%, the stock has underperformed relative to the China Shanghai Composite index over various time frames. The company's return on equity (ROE) is reported at 19.30%, and it maintains an attractive valuation with a price-to-book ratio of 2.76, alongside a dividend yield of 2.6%. This adjustment in evaluation reflects the complexities of the current market landscape for Zhejiang Jolly Pharmaceutical Co., Ltd. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.